

*primary studies - published, non RCT*

## **Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)**

**Code:** CN-XXXXX013    **Year:** 2019    **Date:** 1975

**Author:** Sommerburg O

### **Participants**

15 CF patients

### **Interventions**

A complete dietary supplement consisting of a beef serum hydrolysate, a glucose polymer, and medium-chain triglycerides was given for a year.

### **Outcome measures**

weight, clinical score, serum albumin level, WBC count

### **Main results**

Patients who received the diet showed significant gains in weight, significant increase in clinical score, significant increase in serum albumin level, and a significant drop in the WBC count compared to control patients who did not receive the supplement.

### **See also**

Pneumologie (Stuttgart, Germany), 2019, 73(SUPPL. 1)

### **Keywords**

Adolescent; Amino Acids; Carbohydrates; Child; Infant; non pharmacological intervention - diet; Protein Hydrolysates; Proteins; Supplementation;